Neutropenia is a blood disorder, which is characterized by abnormally low concentration of neutrophils, a type of white blood cell (WBC), in the blood.The market is primarily dominated by biologics and biosimilars whereas other drug classes such as antibiotics and antifungal drugs are also in use.

PART 01: Executive summary 6

PART 02: Scope of the report 17

PART 03: Research Methodology 22

PART 04: Introduction 25

Key market highlights 25

PART 05: Disease overview 26

Neutropenia 26

PART 06: Key clinical trials 33

PART 07: Market landscape 37

Market overview 37

Five forces analysis 40

PART 08: Market segmentation by drug class 41

G-CSF treatment market 41

Antibiotics treatment market 43

Antifungal drugs treatment market 45

Others 46

Geographical segmentation 46

Neutropenia market in Americas 48

Neutropenia market in EMEA 50

Neutropenia market in APAC 52

PART 09: Decision framework 54

PART 10: Drivers and challenges 56

Market drivers 57

Market challenges 60

Impact of drivers and challenges on key customer

segments (pharmacy and hospitals) 62

PART 11: Market trends 63

Evolving payer’s interest toward G-CSF biosimilars 63

Paradigm shift in management of febrile neutropenia 64

Advent of small molecules 64

PART 12: Vendor landscape 66

Competitive scenario 66

PART 13: Key vendor analysis 68

Amgen 68

Novartis 70

Teva Pharmaceutical 73

Other prominent vendors 76

PART 14: Appendix 77

List of abbreviations 77

PART 15: Explore Technavio 78